{"id": "article-22813_0", "title": "A Review of Hereditary Colorectal Cancers -- Continuing Education Activity", "content": "Colorectal cancer is the fourth leading cause of death in the world. Many cases of colorectal cancer are associated with lifestyle factors such as obesity and lack of exercise, inadequate consumption of fruits, vegetables, fiber, fish, vitamin C, dairy products, and vitamin D, and excessive consumption of alcohol and red meat. The inherited colorectal cancer syndromes are a series of diseases in which specific mutations predispose to colorectal cancer. They are more aggressive and have a worse prognosis since they generally form additional tumors and do not always respond to chemotherapy. This activity will review the most common genetic syndromes associated with colorectal cancer and outline the medical and surgical treatment approach according to current evidence. This activity will highlight the role of the interprofessional team in recognizing and treating colorectal cancer.", "contents": "A Review of Hereditary Colorectal Cancers -- Continuing Education Activity. Colorectal cancer is the fourth leading cause of death in the world. Many cases of colorectal cancer are associated with lifestyle factors such as obesity and lack of exercise, inadequate consumption of fruits, vegetables, fiber, fish, vitamin C, dairy products, and vitamin D, and excessive consumption of alcohol and red meat. The inherited colorectal cancer syndromes are a series of diseases in which specific mutations predispose to colorectal cancer. They are more aggressive and have a worse prognosis since they generally form additional tumors and do not always respond to chemotherapy. This activity will review the most common genetic syndromes associated with colorectal cancer and outline the medical and surgical treatment approach according to current evidence. This activity will highlight the role of the interprofessional team in recognizing and treating colorectal cancer."}
{"id": "article-22813_1", "title": "A Review of Hereditary Colorectal Cancers -- Continuing Education Activity", "content": "Objectives: Explain how to counsel a patient about lifestyle to decrease their risk of developing sporadic colorectal cancer. Identify the types of hereditary colorectal cancer toward which the Modified Betheseda Criteria and the Amsterdam II Criteria are geared. Describe a patient presentation consistent with hereditary polyposis colorectal cancer. Outline approaches that the interprofessional care team can use to assist in recognizing, preventing, and managing colorectal cancer. Access free multiple choice questions on this topic.", "contents": "A Review of Hereditary Colorectal Cancers -- Continuing Education Activity. Objectives: Explain how to counsel a patient about lifestyle to decrease their risk of developing sporadic colorectal cancer. Identify the types of hereditary colorectal cancer toward which the Modified Betheseda Criteria and the Amsterdam II Criteria are geared. Describe a patient presentation consistent with hereditary polyposis colorectal cancer. Outline approaches that the interprofessional care team can use to assist in recognizing, preventing, and managing colorectal cancer. Access free multiple choice questions on this topic."}
{"id": "article-22813_2", "title": "A Review of Hereditary Colorectal Cancers -- Introduction", "content": "Colorectal cancer (CRC) is the world's fourth leading cause of death. It has links with inappropriate food habits such as low consumption of fruits, vegetables, fiber, fish, vitamin C, dairy products, and vitamin D, and high consumption of foods containing heme-iron (red and processed meat). Moreover, other factors that increase its incidence include poor lifestyles such as high alcohol consumption, obesity, and lack of exercise. The inherited CRC syndromes are a series of diseases that have specific mutations that predispose to CRC. These are more aggressive and have a worse prognosis since they correlate with other tumors, and some do not respond to chemotherapy.", "contents": "A Review of Hereditary Colorectal Cancers -- Introduction. Colorectal cancer (CRC) is the world's fourth leading cause of death. It has links with inappropriate food habits such as low consumption of fruits, vegetables, fiber, fish, vitamin C, dairy products, and vitamin D, and high consumption of foods containing heme-iron (red and processed meat). Moreover, other factors that increase its incidence include poor lifestyles such as high alcohol consumption, obesity, and lack of exercise. The inherited CRC syndromes are a series of diseases that have specific mutations that predispose to CRC. These are more aggressive and have a worse prognosis since they correlate with other tumors, and some do not respond to chemotherapy."}
{"id": "article-22813_3", "title": "A Review of Hereditary Colorectal Cancers -- Introduction", "content": "Early diagnosis is challenging for physicians due to the absence of pathognomonic clinical findings. The evidence shows that 50% of the patients are asymptomatic and usually present with symptoms (such as rectal bleeding, weight loss, and intestinal obstruction) when the disease is already advanced.\u00a0Familial adenomatous polyposis (FAP) and syndromes not associated with polyposis, such as Lynch syndrome, are the most common cause of the onset of hereditary syndromes.\u00a0When considered together, they represent 6% to 10% of all cases of CRC. [1]", "contents": "A Review of Hereditary Colorectal Cancers -- Introduction. Early diagnosis is challenging for physicians due to the absence of pathognomonic clinical findings. The evidence shows that 50% of the patients are asymptomatic and usually present with symptoms (such as rectal bleeding, weight loss, and intestinal obstruction) when the disease is already advanced.\u00a0Familial adenomatous polyposis (FAP) and syndromes not associated with polyposis, such as Lynch syndrome, are the most common cause of the onset of hereditary syndromes.\u00a0When considered together, they represent 6% to 10% of all cases of CRC. [1]"}
{"id": "article-22813_4", "title": "A Review of Hereditary Colorectal Cancers -- Introduction", "content": "Estimates are that tumors found in young adults are related to hereditary CRC syndromes. This article will review the most common genetic syndromes in the development of CRC and the medical-surgical treatment approach according to current evidence.", "contents": "A Review of Hereditary Colorectal Cancers -- Introduction. Estimates are that tumors found in young adults are related to hereditary CRC syndromes. This article will review the most common genetic syndromes in the development of CRC and the medical-surgical treatment approach according to current evidence."}
{"id": "article-22813_5", "title": "A Review of Hereditary Colorectal Cancers -- Etiology", "content": "Hereditary colorectal cancer (HCRC) is not a single disease; it is a group of diseases or syndromes with a mutational genetic component; these generate a clinically differentiated phenotype. It subdivides into two large HNPCC groups and the HPCC:", "contents": "A Review of Hereditary Colorectal Cancers -- Etiology. Hereditary colorectal cancer (HCRC) is not a single disease; it is a group of diseases or syndromes with a mutational genetic component; these generate a clinically differentiated phenotype. It subdivides into two large HNPCC groups and the HPCC:"}
{"id": "article-22813_6", "title": "A Review of Hereditary Colorectal Cancers -- Etiology", "content": "Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant cancer syndrome; the incidence of this syndrome is\u00a01.7 to 4.2% among all CRCs patients (represents 3 to 8 cases per million inhabitants in the world, according to Globocan 2018). [2] [3] [4] [3]", "contents": "A Review of Hereditary Colorectal Cancers -- Etiology. Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant cancer syndrome; the incidence of this syndrome is\u00a01.7 to 4.2% among all CRCs patients (represents 3 to 8 cases per million inhabitants in the world, according to Globocan 2018). [2] [3] [4] [3]"}
{"id": "article-22813_7", "title": "A Review of Hereditary Colorectal Cancers -- Etiology", "content": "Lynch syndrome (LS) is the commonest of hereditary cancers and correlates with an increased risk of colorectal, endometrium, ovary, stomach, and small bowel cancer.\u00a0LS has associations with mutations of DNA mismatch repair\u00a0(MMR)as MLH1(76%), MSH2(40%), MSH6, PMS2, and EPCAM. [5] LS is incidence represents 3 to 5 cases per million inhabitants, according to Globocan 2018). [6] Sporadic colorectal carcinomas, MLH1-/PMS2-deficient. [7] Muir-Torre syndrome:(\u00a0The genes most commonly mutated MLH1, MSH2, MSH6, and PMS2). Its incidence represents 2 cases per ten million inhabitants, according to Globocan 2018). [8] Turcot syndrome type I: The frequency is approximately 20% to 25% among all TS. It is related to mutations of the MMR gene. [9] Hereditary polyposis colorectal cancer (HPCC) accounts for approximately 3 to 5 % of all CRC cases. [10] [11] (represents 5 to 9 cases per million inhabitants globally, according to Globocan 2018).", "contents": "A Review of Hereditary Colorectal Cancers -- Etiology. Lynch syndrome (LS) is the commonest of hereditary cancers and correlates with an increased risk of colorectal, endometrium, ovary, stomach, and small bowel cancer.\u00a0LS has associations with mutations of DNA mismatch repair\u00a0(MMR)as MLH1(76%), MSH2(40%), MSH6, PMS2, and EPCAM. [5] LS is incidence represents 3 to 5 cases per million inhabitants, according to Globocan 2018). [6] Sporadic colorectal carcinomas, MLH1-/PMS2-deficient. [7] Muir-Torre syndrome:(\u00a0The genes most commonly mutated MLH1, MSH2, MSH6, and PMS2). Its incidence represents 2 cases per ten million inhabitants, according to Globocan 2018). [8] Turcot syndrome type I: The frequency is approximately 20% to 25% among all TS. It is related to mutations of the MMR gene. [9] Hereditary polyposis colorectal cancer (HPCC) accounts for approximately 3 to 5 % of all CRC cases. [10] [11] (represents 5 to 9 cases per million inhabitants globally, according to Globocan 2018)."}
{"id": "article-22813_8", "title": "A Review of Hereditary Colorectal Cancers -- Etiology", "content": "Familial adenomatous polyposis (FAP)\u00a0is related to the germline mutations of the APC gene.\u00a0FAP incidence represents 2 to 3 cases per million inhabitants, according to data from the Danish Polyposis Registry 2017. [12] Adenomatous polyposis syndromes (APC and MUTYH). [13] Juvenile polyposis coli: (BMPR1A and SMAD4). [14] It is\u00a0estimated the incidence of 1 per one million\u00a0inhabitants. [15] [16] Peutz-Jeghers syndrome: (STK11/LKB1), is incidence represents\u00a01.2 per one million inhabitants. [17] [18] PTEN hamartoma tumor syndrome: (PHTS; PTEN). [19] Cowden syndrome:(affecting the PTEN-gene). [20] It\u00a0is incidence represents 6 cases per ten million inhabitants. [21] [22] [23] Turcot syndrome type II: The frequency is approximately 75% to 80% among all TSs. It is related to the APC gene mutation. [24] Gardner syndrome: (involved APC gene). [25] It\u00a0is incidence represents 1 per one million people within the United States. [25]", "contents": "A Review of Hereditary Colorectal Cancers -- Etiology. Familial adenomatous polyposis (FAP)\u00a0is related to the germline mutations of the APC gene.\u00a0FAP incidence represents 2 to 3 cases per million inhabitants, according to data from the Danish Polyposis Registry 2017. [12] Adenomatous polyposis syndromes (APC and MUTYH). [13] Juvenile polyposis coli: (BMPR1A and SMAD4). [14] It is\u00a0estimated the incidence of 1 per one million\u00a0inhabitants. [15] [16] Peutz-Jeghers syndrome: (STK11/LKB1), is incidence represents\u00a01.2 per one million inhabitants. [17] [18] PTEN hamartoma tumor syndrome: (PHTS; PTEN). [19] Cowden syndrome:(affecting the PTEN-gene). [20] It\u00a0is incidence represents 6 cases per ten million inhabitants. [21] [22] [23] Turcot syndrome type II: The frequency is approximately 75% to 80% among all TSs. It is related to the APC gene mutation. [24] Gardner syndrome: (involved APC gene). [25] It\u00a0is incidence represents 1 per one million people within the United States. [25]"}
{"id": "article-22813_9", "title": "A Review of Hereditary Colorectal Cancers -- Epidemiology", "content": "Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related mortality globally. The estimated age-standardized incidence and mortality rates in 2018 worldwide for both sexes of all ages is 19.7 per 100000 inhabitants, and the mortality rate is 8.9 per 100000 patients, according to Globocan.\u00a0The incidence increases significantly by six times when it is related to obesity. [26] The hereditary CRC\u00a0occurs in those individuals with a family history of colorectal cancer with familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer, the most common being Lynch syndrome. [5]", "contents": "A Review of Hereditary Colorectal Cancers -- Epidemiology. Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related mortality globally. The estimated age-standardized incidence and mortality rates in 2018 worldwide for both sexes of all ages is 19.7 per 100000 inhabitants, and the mortality rate is 8.9 per 100000 patients, according to Globocan.\u00a0The incidence increases significantly by six times when it is related to obesity. [26] The hereditary CRC\u00a0occurs in those individuals with a family history of colorectal cancer with familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer, the most common being Lynch syndrome. [5]"}
{"id": "article-22813_10", "title": "A Review of Hereditary Colorectal Cancers -- Epidemiology", "content": "These are detected in 6% to 10% of all CRC diagnosed before age 50; that is, its incidence would be 2 per 100000 inhabitants in the world population. [1] [27] [1] The risk of advanced neoplasia after a small tubular adenoma in the initial colonoscopy is four times higher in patients with a positive fecal immunochemical test. [28] Additionally, the relative risk of colorectal cancer is higher when patients have a history of colon cancer than rectal cancer. [29]", "contents": "A Review of Hereditary Colorectal Cancers -- Epidemiology. These are detected in 6% to 10% of all CRC diagnosed before age 50; that is, its incidence would be 2 per 100000 inhabitants in the world population. [1] [27] [1] The risk of advanced neoplasia after a small tubular adenoma in the initial colonoscopy is four times higher in patients with a positive fecal immunochemical test. [28] Additionally, the relative risk of colorectal cancer is higher when patients have a history of colon cancer than rectal cancer. [29]"}
{"id": "article-22813_11", "title": "A Review of Hereditary Colorectal Cancers -- Pathophysiology", "content": "The mutational mechanisms associated with CRC are:", "contents": "A Review of Hereditary Colorectal Cancers -- Pathophysiology. The mutational mechanisms associated with CRC are:"}
{"id": "article-22813_12", "title": "A Review of Hereditary Colorectal Cancers -- Pathophysiology -- Genomic Instability", "content": "Instability Chromosome: is the most common type found in 85% of the CRCs. [30] This mutation causes the loss of heterozygosity in tumor suppressor genes and mutations in proto-oncogenes. [31] Mutations affect the following genes: APC, TP53, and K-ras, allelic loss of 18q, and aneuploidy.\u00a0For example, FAP develops cancer from this route (CRC risk 90% without colectomy and risk of extracolonic cancers 10 to 99 adenomas). [32] There are many mutations in the APC gene (a large \u201chousekeeping\u201d gene), including micro-deletions and frameshift mutations. More than 60% of the mutations are present at the 5\u2032 ends of the exon on the 5q21 chromosome. [33]", "contents": "A Review of Hereditary Colorectal Cancers -- Pathophysiology -- Genomic Instability. Instability Chromosome: is the most common type found in 85% of the CRCs. [30] This mutation causes the loss of heterozygosity in tumor suppressor genes and mutations in proto-oncogenes. [31] Mutations affect the following genes: APC, TP53, and K-ras, allelic loss of 18q, and aneuploidy.\u00a0For example, FAP develops cancer from this route (CRC risk 90% without colectomy and risk of extracolonic cancers 10 to 99 adenomas). [32] There are many mutations in the APC gene (a large \u201chousekeeping\u201d gene), including micro-deletions and frameshift mutations. More than 60% of the mutations are present at the 5\u2032 ends of the exon on the 5q21 chromosome. [33]"}
{"id": "article-22813_13", "title": "A Review of Hereditary Colorectal Cancers -- Pathophysiology -- Genomic Instability", "content": "Microsatellite instability: It is present in 15% of CRC. [30] It is caused by errors in the repair system due to DNA damage (MMR), mainly due to failure in base complementarity, which generates the expansion of short sequences in tandem and increases the number of mutations. The MMR system is made up of seven genes: hMLH1, hMLH3, hMSH2, hMSH3, hMSH6, hPMS1, and hPMS2; Currently, more than 500 different mutations have been described. [34] For example, LS progresses to cancer from the aforementioned (Lifetime risk of CRC 70%). [32] Cumulative incidence at 75 years for colorectal cancer were 46%, 43%, and 15% in path MLH1, MSH2, and MSH6 carriers, respectively. [35]", "contents": "A Review of Hereditary Colorectal Cancers -- Pathophysiology -- Genomic Instability. Microsatellite instability: It is present in 15% of CRC. [30] It is caused by errors in the repair system due to DNA damage (MMR), mainly due to failure in base complementarity, which generates the expansion of short sequences in tandem and increases the number of mutations. The MMR system is made up of seven genes: hMLH1, hMLH3, hMSH2, hMSH3, hMSH6, hPMS1, and hPMS2; Currently, more than 500 different mutations have been described. [34] For example, LS progresses to cancer from the aforementioned (Lifetime risk of CRC 70%). [32] Cumulative incidence at 75 years for colorectal cancer were 46%, 43%, and 15% in path MLH1, MSH2, and MSH6 carriers, respectively. [35]"}
{"id": "article-22813_14", "title": "A Review of Hereditary Colorectal Cancers -- Pathophysiology", "content": "Epigenetic (DNA methylation) Methylation of CpG islands occurs in sporadic\u00a0CRC 15% , and also it affects the expression of DNA repair genes or Mismatch genes. [36] [37]", "contents": "A Review of Hereditary Colorectal Cancers -- Pathophysiology. Epigenetic (DNA methylation) Methylation of CpG islands occurs in sporadic\u00a0CRC 15% , and also it affects the expression of DNA repair genes or Mismatch genes. [36] [37]"}
{"id": "article-22813_15", "title": "A Review of Hereditary Colorectal Cancers -- History and Physical", "content": "We will focus on the two most frequent pathologies of hereditary colorectal cancer according to the polyposis classification:", "contents": "A Review of Hereditary Colorectal Cancers -- History and Physical. We will focus on the two most frequent pathologies of hereditary colorectal cancer according to the polyposis classification:"}
{"id": "article-22813_16", "title": "A Review of Hereditary Colorectal Cancers -- History and Physical", "content": "HNPCC - Lynch syndrome (LS): Characteristically presents with flat polyps located in the right colon, which generate CRC and other cancers (endometrium, stomach, ovary, pancreas, ureter and renal pelvis, cerebral glioblastoma, biliary tract, cancer of the small intestine, sebaceous carcinomas and keratoacanthomas). Endometrial cancer occurs in relatively young women. [38] The diagnosis is challenging for the doctor due to the absence of pathognomonic clinical signs. A genetic study is required to establish the definitive diagnosis, so it is recommended to make a previous selection of these patients with the criteria of Bethesda and Amsterdam. [39]", "contents": "A Review of Hereditary Colorectal Cancers -- History and Physical. HNPCC - Lynch syndrome (LS): Characteristically presents with flat polyps located in the right colon, which generate CRC and other cancers (endometrium, stomach, ovary, pancreas, ureter and renal pelvis, cerebral glioblastoma, biliary tract, cancer of the small intestine, sebaceous carcinomas and keratoacanthomas). Endometrial cancer occurs in relatively young women. [38] The diagnosis is challenging for the doctor due to the absence of pathognomonic clinical signs. A genetic study is required to establish the definitive diagnosis, so it is recommended to make a previous selection of these patients with the criteria of Bethesda and Amsterdam. [39]"}
{"id": "article-22813_17", "title": "A Review of Hereditary Colorectal Cancers -- History and Physical", "content": "HPCC) - Familial adenomatous polyposis (FAP): It is characterized by hundreds or thousands of precancerous adenomatous polyps, which generate CRC and other cancers, Also may occur extracolonic manifestations (desmoid tumor, osteomas, epidermoid cysts, papillary thyroid carcinoma, pancreatic carcinoma, gastric cancer, duodenal cancer, hepatobiliary and CNS tumors), this is due to mutations in the gene (APC), which controls cell proliferation and the regulation of a new long non-coding RNA (lncRNA). [40] It is classified clinically in two ways:", "contents": "A Review of Hereditary Colorectal Cancers -- History and Physical. HPCC) - Familial adenomatous polyposis (FAP): It is characterized by hundreds or thousands of precancerous adenomatous polyps, which generate CRC and other cancers, Also may occur extracolonic manifestations (desmoid tumor, osteomas, epidermoid cysts, papillary thyroid carcinoma, pancreatic carcinoma, gastric cancer, duodenal cancer, hepatobiliary and CNS tumors), this is due to mutations in the gene (APC), which controls cell proliferation and the regulation of a new long non-coding RNA (lncRNA). [40] It is classified clinically in two ways:"}
{"id": "article-22813_18", "title": "A Review of Hereditary Colorectal Cancers -- History and Physical", "content": "Classic FAP: Consists of the involvement of the entire colon with the appearance of 100 to 1000 adenomatous polyps, the age of onset of polyps comprises between 10 and 20 years of age; estimates are that the diagnosis of CRC corresponds to 30 to 40 years of age,\u00a0It correlates with the majority of cancers described above, which increases comorbidity. [41] [42] Attenuated FAP: Frequently affects the right colon, with an appearance of 10 to 100 adenomatous polyps, the age of onset of polyps between 20 to 30 years of age; estimates are the diagnosis of CRC corresponds to 40 to 50 years of age. It commonly carries associations with gastric, duodenal, and thyroid cancer. [43] [44]", "contents": "A Review of Hereditary Colorectal Cancers -- History and Physical. Classic FAP: Consists of the involvement of the entire colon with the appearance of 100 to 1000 adenomatous polyps, the age of onset of polyps comprises between 10 and 20 years of age; estimates are that the diagnosis of CRC corresponds to 30 to 40 years of age,\u00a0It correlates with the majority of cancers described above, which increases comorbidity. [41] [42] Attenuated FAP: Frequently affects the right colon, with an appearance of 10 to 100 adenomatous polyps, the age of onset of polyps between 20 to 30 years of age; estimates are the diagnosis of CRC corresponds to 40 to 50 years of age. It commonly carries associations with gastric, duodenal, and thyroid cancer. [43] [44]"}
{"id": "article-22813_19", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation", "content": "The diagnostic basis of hereditary CRC is from clinical findings, family history, genetic tests, and diagnostic images (see Table. Colorectal Carcinoma Screening Guidelines).", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation. The diagnostic basis of hereditary CRC is from clinical findings, family history, genetic tests, and diagnostic images (see Table. Colorectal Carcinoma Screening Guidelines)."}
{"id": "article-22813_20", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation", "content": "Physical examination: Should include evaluation of adenopathies, mainly supraclavicular, cervical and axillary, digital rectal examination, abdominal palpation in search of masses or ascites, hepatomegaly suggesting a hepatic metastatic compromise.", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation. Physical examination: Should include evaluation of adenopathies, mainly supraclavicular, cervical and axillary, digital rectal examination, abdominal palpation in search of masses or ascites, hepatomegaly suggesting a hepatic metastatic compromise."}
{"id": "article-22813_21", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation", "content": "Total\u00a0colonoscopy: It is a gold standard technique since it allows the resection and biopsy of the lesions observed during the procedure. [45] Moreover, endoscopy with a colonic capsule is a promising technique for noninvasive colon screening; however, it is a risk to detect polyps and not be able to biopsy them. [46] Family history : more than one criterion raises suspicion of LS.", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation. Total\u00a0colonoscopy: It is a gold standard technique since it allows the resection and biopsy of the lesions observed during the procedure. [45] Moreover, endoscopy with a colonic capsule is a promising technique for noninvasive colon screening; however, it is a risk to detect polyps and not be able to biopsy them. [46] Family history : more than one criterion raises suspicion of LS."}
{"id": "article-22813_22", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation", "content": "Modified Bethesda criteria, which are: Patients with CRC belong to families that meet the criteria of Amsterdam Patients with two neoplasms associated with HNPCC, including synchronous or metachronous CRC and extracolonic cancer (endometrium, ovary, gastric, hepatobiliary, small intestine, ureter, or renal pelvis) Patients with CRC and a first-degree relative with CRC, extracolonic neoplasm associated with HNPCC or colorectal adenoma; one of the cancers diagnosed before 50 and the adenoma before 40 years of age Patients with CRC or endometrial cancer are diagnosed before 50 years of age Patients with CRC in the right colon and histologically undifferentiated are diagnosed before 50 Patients with CCR-type cells in the signet ring (composed of more than 50% of signet ring cells) were diagnosed before 50 Patients with colorectal adenoma are diagnosed before 40 years of age [47]", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation. Modified Bethesda criteria, which are: Patients with CRC belong to families that meet the criteria of Amsterdam Patients with two neoplasms associated with HNPCC, including synchronous or metachronous CRC and extracolonic cancer (endometrium, ovary, gastric, hepatobiliary, small intestine, ureter, or renal pelvis) Patients with CRC and a first-degree relative with CRC, extracolonic neoplasm associated with HNPCC or colorectal adenoma; one of the cancers diagnosed before 50 and the adenoma before 40 years of age Patients with CRC or endometrial cancer are diagnosed before 50 years of age Patients with CRC in the right colon and histologically undifferentiated are diagnosed before 50 Patients with CCR-type cells in the signet ring (composed of more than 50% of signet ring cells) were diagnosed before 50 Patients with colorectal adenoma are diagnosed before 40 years of age [47]"}
{"id": "article-22813_23", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation", "content": "Amsterdam criteria II, which are: Three or more relatives affected by a neoplasm associated with HNPCC (CRC, cancer of the endometrium, small intestine, ureter, or renal pelvis), one of them being a first-degree relative of the other two, and; Two or more successive generations were affected, and; One or more relatives affected by CRC were diagnosed before 50 years of age, and; Exclusion of FAP in cases of CCR. [48]", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation. Amsterdam criteria II, which are: Three or more relatives affected by a neoplasm associated with HNPCC (CRC, cancer of the endometrium, small intestine, ureter, or renal pelvis), one of them being a first-degree relative of the other two, and; Two or more successive generations were affected, and; One or more relatives affected by CRC were diagnosed before 50 years of age, and; Exclusion of FAP in cases of CCR. [48]"}
{"id": "article-22813_24", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation", "content": "Molecular and genetic testing: LS\u00a0Diagnosis is made by tumor testing with MMR immunohistochemistry and PCR for MSI (microsatellite instability) , a genetic phenotype that characterizes these tumors. Therefore, having a positive genetic test (MSI), a positive Bethesda or Amsterdam item, and the tumor located on the right side of the colon are highly suspicious findings of Lynch syndrome. [49] When colonic polyposis presents in a single person with a negative family history, consideration should be to test for a de novo APC mutation; if negative, follow with MUTYH genetic testing when colonic polyposis is present only in siblings, consider recessive inheritance, and test for MUTYH first. [40]", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation. Molecular and genetic testing: LS\u00a0Diagnosis is made by tumor testing with MMR immunohistochemistry and PCR for MSI (microsatellite instability) , a genetic phenotype that characterizes these tumors. Therefore, having a positive genetic test (MSI), a positive Bethesda or Amsterdam item, and the tumor located on the right side of the colon are highly suspicious findings of Lynch syndrome. [49] When colonic polyposis presents in a single person with a negative family history, consideration should be to test for a de novo APC mutation; if negative, follow with MUTYH genetic testing when colonic polyposis is present only in siblings, consider recessive inheritance, and test for MUTYH first. [40]"}
{"id": "article-22813_25", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation", "content": "Diagnostic Imaging: It is suggested to perform computed tomography with the contrast of the chest, abdomen, and pelvis to estimate the stage of the disease in all patients with colorectal cancer. Additionally, It is suggested to perform computed tomography or magnetic resonance imaging of the pelvis to assess the status of the mesorectal margin in selected cases.", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation. Diagnostic Imaging: It is suggested to perform computed tomography with the contrast of the chest, abdomen, and pelvis to estimate the stage of the disease in all patients with colorectal cancer. Additionally, It is suggested to perform computed tomography or magnetic resonance imaging of the pelvis to assess the status of the mesorectal margin in selected cases."}
{"id": "article-22813_26", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation", "content": "Specific aspects of individuals' family history of CRC would influence the age at which, planning to begin screening and the frequency of screening. Following details with the family history of the number of first-degree relatives should be considered before planning for a screening schedule; Established diagnosis of CRC Advanced polyp that harbors any of the following characteristics: Adenoma size of equal to or greater than 1 cm Presence of high-grade dysplasia Adenoma with a villous component Advanced sessile serrated lesion with any of the following characteristics: Sessile polyp with a size equal to or greater than 1 cm Serrated adenoma with equal or greater than 1 cm size Presence of dysplasia in a sessile serrated polyp", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation. Specific aspects of individuals' family history of CRC would influence the age at which, planning to begin screening and the frequency of screening. Following details with the family history of the number of first-degree relatives should be considered before planning for a screening schedule; Established diagnosis of CRC Advanced polyp that harbors any of the following characteristics: Adenoma size of equal to or greater than 1 cm Presence of high-grade dysplasia Adenoma with a villous component Advanced sessile serrated lesion with any of the following characteristics: Sessile polyp with a size equal to or greater than 1 cm Serrated adenoma with equal or greater than 1 cm size Presence of dysplasia in a sessile serrated polyp"}
{"id": "article-22813_27", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation", "content": "According to the response to the above questions, the following screening schedules are recommended. If\u00a0equal to or more than one first-degree relative is affected, the screening is to be initiated either at the age of 40 or at the age equal to 10 years younger than the affected FDR, whichever comes earlier. Moreover, a continuous schedule plan with either colonoscopy every five years or\u00a0annual fecal immunochemical testing (FIT) are recommended.", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation. According to the response to the above questions, the following screening schedules are recommended. If\u00a0equal to or more than one first-degree relative is affected, the screening is to be initiated either at the age of 40 or at the age equal to 10 years younger than the affected FDR, whichever comes earlier. Moreover, a continuous schedule plan with either colonoscopy every five years or\u00a0annual fecal immunochemical testing (FIT) are recommended."}
{"id": "article-22813_28", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation", "content": "Consequently, if the first-degree relative has a polyp without a well-established tissue diagnosis of either an advanced adenoma or a serrated polyp, the individual would be categorized as average risk.", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation. Consequently, if the first-degree relative has a polyp without a well-established tissue diagnosis of either an advanced adenoma or a serrated polyp, the individual would be categorized as average risk."}
{"id": "article-22813_29", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation -- High-Risk Syndrome Screenings", "content": "Specific screening schedules should be planned for individuals with Lynch-associated cancers. The schedule should be organized based on the following characteristics; 1. personal and family history of cancer, 2. the gene affected, and 3. the mode of ascertainment of the familial mutation. According to some expert opinions, and due to the significantly lower lifetime cancer risk for carriers of germline PMS2 mutations, screening recommendations must be tailored to the MMR gene alone. Moreover,\u00a0a later mean age of colorectal cancer (CRC) onset in germline MSH6 carriers should dictate a modified screening schedule. Collectively, screening is recommended for the following individuals considering the\u00a0Lynch-associated cancers:", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation -- High-Risk Syndrome Screenings. Specific screening schedules should be planned for individuals with Lynch-associated cancers. The schedule should be organized based on the following characteristics; 1. personal and family history of cancer, 2. the gene affected, and 3. the mode of ascertainment of the familial mutation. According to some expert opinions, and due to the significantly lower lifetime cancer risk for carriers of germline PMS2 mutations, screening recommendations must be tailored to the MMR gene alone. Moreover,\u00a0a later mean age of colorectal cancer (CRC) onset in germline MSH6 carriers should dictate a modified screening schedule. Collectively, screening is recommended for the following individuals considering the\u00a0Lynch-associated cancers:"}
{"id": "article-22813_30", "title": "A Review of Hereditary Colorectal Cancers -- Evaluation -- High-Risk Syndrome Screenings", "content": "Individuals with either a pathogenic germline mutation in the DNA mismatch repair (MMR) genes or\u00a0epithelial cellular adhesion molecule (EPCAM)  deletions that can inactivate Mutation S Homolog 2 (MSH2) Individuals at risk for Lynch syndrome, including individuals in families meeting Amsterdam I or II criteria and individuals meeting revised Bethesda guidelines High-risk individuals with an equal or greater than 2.5 to 5 % risk for MMR mutation according to the prediction models [50]", "contents": "A Review of Hereditary Colorectal Cancers -- Evaluation -- High-Risk Syndrome Screenings. Individuals with either a pathogenic germline mutation in the DNA mismatch repair (MMR) genes or\u00a0epithelial cellular adhesion molecule (EPCAM)  deletions that can inactivate Mutation S Homolog 2 (MSH2) Individuals at risk for Lynch syndrome, including individuals in families meeting Amsterdam I or II criteria and individuals meeting revised Bethesda guidelines High-risk individuals with an equal or greater than 2.5 to 5 % risk for MMR mutation according to the prediction models [50]"}
{"id": "article-22813_31", "title": "A Review of Hereditary Colorectal Cancers -- Treatment / Management", "content": "Management of patients with HCCR is multidisciplinary and mainly stems from patients' specific findings.", "contents": "A Review of Hereditary Colorectal Cancers -- Treatment / Management. Management of patients with HCCR is multidisciplinary and mainly stems from patients' specific findings."}
{"id": "article-22813_32", "title": "A Review of Hereditary Colorectal Cancers -- Treatment / Management", "content": "Chemotherapy: Depending on their genetic mutation, hereditary CRCs may respond differently to traditional chemotherapy regimens. The microsatellite instability in many cases reflects a difference in the biological characteristics of the tumor, possibly with a unique susceptibility to immunotherapy. [51] [52] High-risk rectal cancers require neoadjuvant chemotherapy along with radiotherapy. [53]", "contents": "A Review of Hereditary Colorectal Cancers -- Treatment / Management. Chemotherapy: Depending on their genetic mutation, hereditary CRCs may respond differently to traditional chemotherapy regimens. The microsatellite instability in many cases reflects a difference in the biological characteristics of the tumor, possibly with a unique susceptibility to immunotherapy. [51] [52] High-risk rectal cancers require neoadjuvant chemotherapy along with radiotherapy. [53]"}
{"id": "article-22813_33", "title": "A Review of Hereditary Colorectal Cancers -- Treatment / Management", "content": "Current ASCO, NCCN, and ESMO guidelines strongly recommend adjuvant therapy for selected stage II with high-risk/pMMR/MSI-S disease and all stage III (node-positive).\u00a0The guidelines advocate administering adjuvant chemotherapy (FOLFOX or CAPOX) within 6 to 8 weeks after surgical resection, pending recovery of the patient's health.", "contents": "A Review of Hereditary Colorectal Cancers -- Treatment / Management. Current ASCO, NCCN, and ESMO guidelines strongly recommend adjuvant therapy for selected stage II with high-risk/pMMR/MSI-S disease and all stage III (node-positive).\u00a0The guidelines advocate administering adjuvant chemotherapy (FOLFOX or CAPOX) within 6 to 8 weeks after surgical resection, pending recovery of the patient's health."}
{"id": "article-22813_34", "title": "A Review of Hereditary Colorectal Cancers -- Treatment / Management", "content": "FOLFOX (5-fluorouracil plus + leucovorin plus +oxaliplatin) is the first-line modern chemotherapy for metastatic disease more effective than the obsolete single-agent chemotherapy (5-fluorouracil) (HR for SLP: 0.59, 95% CI 0.49 to 0.73, 2 RCT),\u00a0 (HR for OS: 0.69, 95% CI 0.51 to 0.94, 1 RCT). [54]", "contents": "A Review of Hereditary Colorectal Cancers -- Treatment / Management. FOLFOX (5-fluorouracil plus + leucovorin plus +oxaliplatin) is the first-line modern chemotherapy for metastatic disease more effective than the obsolete single-agent chemotherapy (5-fluorouracil) (HR for SLP: 0.59, 95% CI 0.49 to 0.73, 2 RCT),\u00a0 (HR for OS: 0.69, 95% CI 0.51 to 0.94, 1 RCT). [54]"}
{"id": "article-22813_35", "title": "A Review of Hereditary Colorectal Cancers -- Treatment / Management", "content": "FOLFIRI\u00a0(5-fluorouracil plus + leucovorin plus + irinotecan) is the second most effective chemotherapy in metastatic CRC and is either first or second line. (HR for OS: 0.58, 95% CI 0.43 to 0.80, 1 RCT).", "contents": "A Review of Hereditary Colorectal Cancers -- Treatment / Management. FOLFIRI\u00a0(5-fluorouracil plus + leucovorin plus + irinotecan) is the second most effective chemotherapy in metastatic CRC and is either first or second line. (HR for OS: 0.58, 95% CI 0.43 to 0.80, 1 RCT)."}
{"id": "article-22813_36", "title": "A Review of Hereditary Colorectal Cancers -- Treatment / Management", "content": "Combinations based on irinotecan were more effective than irinotecan alone (HR for PFS: 0.68, 95% CI 0.60 to 0.76, 6 RCT) [Level II].\u00a0Targeted agents increased the efficacy of conventional chemotherapy when considered together (HR for OS: 0.84, 95% CI 0.77 to 0.91, 6 RCT) and when bevacizumab alone (HR for PFS: 0.67, 95% CI 0.60 to 0.75, 4 RCT). [54]", "contents": "A Review of Hereditary Colorectal Cancers -- Treatment / Management. Combinations based on irinotecan were more effective than irinotecan alone (HR for PFS: 0.68, 95% CI 0.60 to 0.76, 6 RCT) [Level II].\u00a0Targeted agents increased the efficacy of conventional chemotherapy when considered together (HR for OS: 0.84, 95% CI 0.77 to 0.91, 6 RCT) and when bevacizumab alone (HR for PFS: 0.67, 95% CI 0.60 to 0.75, 4 RCT). [54]"}
{"id": "article-22813_37", "title": "A Review of Hereditary Colorectal Cancers -- Treatment / Management", "content": "In metastatic colorectal cancer, monoclonal antibodies are used (bevacizumab, cetuximab, and panitumumab)\u00a0 in combination with chemotherapy. There is a distinct benefit in the addition of bevacizumab to chemotherapy for tumors on the right side of cetuximab to chemotherapy for tumors on the left side (for RAS wild-type tumors) to oxaliplatin- and irinotecan-based regimens which can be a consideration for first-line therapy. [55]", "contents": "A Review of Hereditary Colorectal Cancers -- Treatment / Management. In metastatic colorectal cancer, monoclonal antibodies are used (bevacizumab, cetuximab, and panitumumab)\u00a0 in combination with chemotherapy. There is a distinct benefit in the addition of bevacizumab to chemotherapy for tumors on the right side of cetuximab to chemotherapy for tumors on the left side (for RAS wild-type tumors) to oxaliplatin- and irinotecan-based regimens which can be a consideration for first-line therapy. [55]"}
{"id": "article-22813_38", "title": "A Review of Hereditary Colorectal Cancers -- Treatment / Management", "content": "A meta-analysis including the TAILOR and the PRIME study suggests that primary tumor location predicted a survival benefit when adding the anti-epidermal growth factor receptor antibody to FOLFOX regimen in RAS & NRAS-wild metastatic CRC patients (OS, HR for left-sided: 0.71; 95% CI: 0.59-0.85; P=.0002 and HR for right-sided: 0.90; 95% CI: 0.65-1.25; P=.53). The efficacy was similar in patients with wild molecular characteristics RAS / BRAF. [56]", "contents": "A Review of Hereditary Colorectal Cancers -- Treatment / Management. A meta-analysis including the TAILOR and the PRIME study suggests that primary tumor location predicted a survival benefit when adding the anti-epidermal growth factor receptor antibody to FOLFOX regimen in RAS & NRAS-wild metastatic CRC patients (OS, HR for left-sided: 0.71; 95% CI: 0.59-0.85; P=.0002 and HR for right-sided: 0.90; 95% CI: 0.65-1.25; P=.53). The efficacy was similar in patients with wild molecular characteristics RAS / BRAF. [56]"}
{"id": "article-22813_39", "title": "A Review of Hereditary Colorectal Cancers -- Treatment / Management", "content": "Radiotherapy: Preoperative radiotherapy\u00a0(hypofractionated) with chemotherapy is recommended in patients with stage II and III rectal cancer or unresectable residual tumor (positive margins), according to the report of anatomopathological findings of the surgical specimen. [57] The use of radiotherapy is limited to palliative therapy for selected cases of metastasis (bone, brain). [58]", "contents": "A Review of Hereditary Colorectal Cancers -- Treatment / Management. Radiotherapy: Preoperative radiotherapy\u00a0(hypofractionated) with chemotherapy is recommended in patients with stage II and III rectal cancer or unresectable residual tumor (positive margins), according to the report of anatomopathological findings of the surgical specimen. [57] The use of radiotherapy is limited to palliative therapy for selected cases of metastasis (bone, brain). [58]"}
{"id": "article-22813_40", "title": "A Review of Hereditary Colorectal Cancers -- Treatment / Management", "content": "Surgery: The appropriate surgical option for patients with colon cancer and LS (total abdominal colectomy or segmental colectomy with ileorectal anastomosis) will depend on the risk factors. The surgical preferences of the patient, with special emphasis on the age of the patient and the capacity of the patient to follow intensive surveillance, [59] but currently, segmental resection is the most performed surgical method in these cases. [60] Also, patients should be offered the option of prophylactically extended surgery (hysterectomy and oophorectomy) if possible in postmenopausal women. [61] [62]", "contents": "A Review of Hereditary Colorectal Cancers -- Treatment / Management. Surgery: The appropriate surgical option for patients with colon cancer and LS (total abdominal colectomy or segmental colectomy with ileorectal anastomosis) will depend on the risk factors. The surgical preferences of the patient, with special emphasis on the age of the patient and the capacity of the patient to follow intensive surveillance, [59] but currently, segmental resection is the most performed surgical method in these cases. [60] Also, patients should be offered the option of prophylactically extended surgery (hysterectomy and oophorectomy) if possible in postmenopausal women. [61] [62]"}
{"id": "article-22813_41", "title": "A Review of Hereditary Colorectal Cancers -- Treatment / Management", "content": "In FAP, prophylactic colectomy is an important option to prevent CRC. [63] The preventive surgical approach is limited for patients with attenuated FAP, delayed colectomy time, and increased standardization of laparoscopic surgery. [64] However, surveillance and surgical management planning should follow a thorough assessment of familial cancer risk. [65]", "contents": "A Review of Hereditary Colorectal Cancers -- Treatment / Management. In FAP, prophylactic colectomy is an important option to prevent CRC. [63] The preventive surgical approach is limited for patients with attenuated FAP, delayed colectomy time, and increased standardization of laparoscopic surgery. [64] However, surveillance and surgical management planning should follow a thorough assessment of familial cancer risk. [65]"}
{"id": "article-22813_42", "title": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis", "content": "Gardner syndrome: is a variant of FAP and is an autosomal dominant inherited disease characterized by multiple intestinal polyps together with extra-intestinal manifestations including multiple osteomas, connective tissue tumors, thyroid carcinomas, hypertrophied pigmented epithelium of the retina, and also frequent retained supernumerary teeth and odontomas. [25] This condition carries a high risk of developing colon cancer. [66] Muir-Torre syndrome: MTS\u00a0is a rare subtype of LS\u00a0characterized by sebaceous neoplasms of the skin and visceral malignancies, with colonic carcinoma being the most common. [67]", "contents": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis. Gardner syndrome: is a variant of FAP and is an autosomal dominant inherited disease characterized by multiple intestinal polyps together with extra-intestinal manifestations including multiple osteomas, connective tissue tumors, thyroid carcinomas, hypertrophied pigmented epithelium of the retina, and also frequent retained supernumerary teeth and odontomas. [25] This condition carries a high risk of developing colon cancer. [66] Muir-Torre syndrome: MTS\u00a0is a rare subtype of LS\u00a0characterized by sebaceous neoplasms of the skin and visceral malignancies, with colonic carcinoma being the most common. [67]"}
{"id": "article-22813_43", "title": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis", "content": "Turcot syndrome: TS\u00a0is the association of primary brain tumors.\u00a0It divides into two subtypes: TS type I (Intestinal polyps are large, fewer in number than 100, and are apt to undergo a malignant change. Associated brain tumor is usually a glioblastoma or an astrocytoma.) and TS\u00a0type II (Familial adenomatous polyposis-associated type. There is a predisposition to the development of medulloblastoma.) [68] Tumors can also arise from the spinal cord, manifesting with symptoms of spinal cord compression. [69]", "contents": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis. Turcot syndrome: TS\u00a0is the association of primary brain tumors.\u00a0It divides into two subtypes: TS type I (Intestinal polyps are large, fewer in number than 100, and are apt to undergo a malignant change. Associated brain tumor is usually a glioblastoma or an astrocytoma.) and TS\u00a0type II (Familial adenomatous polyposis-associated type. There is a predisposition to the development of medulloblastoma.) [68] Tumors can also arise from the spinal cord, manifesting with symptoms of spinal cord compression. [69]"}
{"id": "article-22813_44", "title": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis", "content": "Juvenile polyposis coli: JPC is a rare disease characterized by juvenile hamartomatous polyps in the gastrointestinal tract.\u00a0The lifetime risk of CRC is 20%. [70] JPC is diagnosed with more than five juvenile polyps in the colon and/or rectum; the presence of juvenile polyps along the digestive tract, including the stomach; the presence of any number of juvenile polyps in association with a family history of JIP. [71] Clinical signs include isolated rectal bleeding, anemia, abdominal pain, intestinal invaginations, diarrhea, rectal prolapse, and spontaneous anal elimination of polyps in juvenile polyposis coli and generalized juvenile polyposis. Other associated signs may include growth retardation and edema. [72]", "contents": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis. Juvenile polyposis coli: JPC is a rare disease characterized by juvenile hamartomatous polyps in the gastrointestinal tract.\u00a0The lifetime risk of CRC is 20%. [70] JPC is diagnosed with more than five juvenile polyps in the colon and/or rectum; the presence of juvenile polyps along the digestive tract, including the stomach; the presence of any number of juvenile polyps in association with a family history of JIP. [71] Clinical signs include isolated rectal bleeding, anemia, abdominal pain, intestinal invaginations, diarrhea, rectal prolapse, and spontaneous anal elimination of polyps in juvenile polyposis coli and generalized juvenile polyposis. Other associated signs may include growth retardation and edema. [72]"}
{"id": "article-22813_45", "title": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis", "content": "Peutz-Jeghers Syndrome: PJS is characterized by the pigmentation of mucocutaneous melanin and multiple gastrointestinal polyposes. The clinical manifestations mainly included black spots, abdominal pain, and anemia. [73] These polyps have a higher risk of developing GI cancers of the colorectal, pancreatic, and gastric organs, in addition to a wide variety of non-GI epithelial malignancies, such as cancers of the breast, uterus, cervix, and ovary, testicular, and lung (see Image. Breast Cancer Metastasis Sites).\u00a0The lifetime risk of CRC is 39%. [74] Patients with PJS present a high risk of intussusception and should receive regular follow-up due to the high risk of cancer and the possibility of relapse. [75]", "contents": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis. Peutz-Jeghers Syndrome: PJS is characterized by the pigmentation of mucocutaneous melanin and multiple gastrointestinal polyposes. The clinical manifestations mainly included black spots, abdominal pain, and anemia. [73] These polyps have a higher risk of developing GI cancers of the colorectal, pancreatic, and gastric organs, in addition to a wide variety of non-GI epithelial malignancies, such as cancers of the breast, uterus, cervix, and ovary, testicular, and lung (see Image. Breast Cancer Metastasis Sites).\u00a0The lifetime risk of CRC is 39%. [74] Patients with PJS present a high risk of intussusception and should receive regular follow-up due to the high risk of cancer and the possibility of relapse. [75]"}
{"id": "article-22813_46", "title": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis", "content": "Hamartoma tumor syndrome: This is called PTEN (PHTS). [76] PTEN correlates with multiple benign diseases (macrocephaly, Hashimoto's thyroiditis, mucocutaneous hamartomas, colon polyps, and vascular malformations) and malignant tumors (breast, thyroid, renal, endometrial, and colon cancer), [76] as well as neurodevelopmental disorders such as autism. [77] PHTS patients may also demonstrate an increased risk of immunological dysregulation, including autoimmunity and immune deficiencies. [19]", "contents": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis. Hamartoma tumor syndrome: This is called PTEN (PHTS). [76] PTEN correlates with multiple benign diseases (macrocephaly, Hashimoto's thyroiditis, mucocutaneous hamartomas, colon polyps, and vascular malformations) and malignant tumors (breast, thyroid, renal, endometrial, and colon cancer), [76] as well as neurodevelopmental disorders such as autism. [77] PHTS patients may also demonstrate an increased risk of immunological dysregulation, including autoimmunity and immune deficiencies. [19]"}
{"id": "article-22813_47", "title": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis", "content": "Cowden syndrome: CS classically is characterized by multiple hamartomas that can occur in any organ, macrocephaly, mucocutaneous lesions, an increased risk of breast and thyroid cancers, and ovarian and colon cancer.\u00a0The lifetime risk of CRC is 13%. [22] [78]", "contents": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis. Cowden syndrome: CS classically is characterized by multiple hamartomas that can occur in any organ, macrocephaly, mucocutaneous lesions, an increased risk of breast and thyroid cancers, and ovarian and colon cancer.\u00a0The lifetime risk of CRC is 13%. [22] [78]"}
{"id": "article-22813_48", "title": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis", "content": "Bannayan-Riley-Ruvalcaba syndrome: BRRS\u00a0is a congenital disorder frequently characterized by hamartomatous intestinal polyps, lipomas, macrocephaly, and genital lentiginosis. BRRS patients with a PTEN mutation share the same risk of developing cancer as patients with CS. [79]", "contents": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis. Bannayan-Riley-Ruvalcaba syndrome: BRRS\u00a0is a congenital disorder frequently characterized by hamartomatous intestinal polyps, lipomas, macrocephaly, and genital lentiginosis. BRRS patients with a PTEN mutation share the same risk of developing cancer as patients with CS. [79]"}
{"id": "article-22813_49", "title": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis", "content": "Proteus syndromes: PS is a disorder characterized by progressive excessive growth at the level of the skeleton, skin, fat, and central nervous system, with few hamartomatous polyps. Complications include hemimegaloencephaly, bullous lung disease, pulmonary embolism, and deep vein thrombosis. The tumors are usually benign, although there are reports of rare cases of malignant tumors. [80]", "contents": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis. Proteus syndromes: PS is a disorder characterized by progressive excessive growth at the level of the skeleton, skin, fat, and central nervous system, with few hamartomatous polyps. Complications include hemimegaloencephaly, bullous lung disease, pulmonary embolism, and deep vein thrombosis. The tumors are usually benign, although there are reports of rare cases of malignant tumors. [80]"}
{"id": "article-22813_50", "title": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis", "content": "Solamen syndrome: The  term 'SOLAMEN syndrome' \"Segmental Overgrowth, Lipomatosis, Arteriovenous Malformation, and Epidermal Nevus.\" These patients are carriers of germline mutations in the phosphatase and PTEN homologs. [81]", "contents": "A Review of Hereditary Colorectal Cancers -- Differential Diagnosis. Solamen syndrome: The  term 'SOLAMEN syndrome' \"Segmental Overgrowth, Lipomatosis, Arteriovenous Malformation, and Epidermal Nevus.\" These patients are carriers of germline mutations in the phosphatase and PTEN homologs. [81]"}
{"id": "article-22813_51", "title": "A Review of Hereditary Colorectal Cancers -- Surgical Oncology", "content": "Surgical management should be planned considering the specific hereditary colorectal cancer. Accordingly, the treatment of choice for patients with attenuated and familial adenomatous polyposis, with a significantly large number of rectal adenomas, is proctocolectomy with ileostomy or ileal-pouch anal anastomosis (IPAA). However, the timing of treatment should be individualized. On the other hand, if all of the rectal adenomas greater than 5 mm in size can be removed endoscopically, rectal sparing alternatives with total colectomy with ileorectal anastomosis (TAC-IRA) is the preferred management. Moreover, in patients with greater than 20-lifetime adenomas, MUTYH-associated polyposis (MAP) should be considered. Accordingly, patients with biallelic MYH mutations are recommended for annual colonoscopy and polypectomy for polyps that can be removed endoscopically. [82]", "contents": "A Review of Hereditary Colorectal Cancers -- Surgical Oncology. Surgical management should be planned considering the specific hereditary colorectal cancer. Accordingly, the treatment of choice for patients with attenuated and familial adenomatous polyposis, with a significantly large number of rectal adenomas, is proctocolectomy with ileostomy or ileal-pouch anal anastomosis (IPAA). However, the timing of treatment should be individualized. On the other hand, if all of the rectal adenomas greater than 5 mm in size can be removed endoscopically, rectal sparing alternatives with total colectomy with ileorectal anastomosis (TAC-IRA) is the preferred management. Moreover, in patients with greater than 20-lifetime adenomas, MUTYH-associated polyposis (MAP) should be considered. Accordingly, patients with biallelic MYH mutations are recommended for annual colonoscopy and polypectomy for polyps that can be removed endoscopically. [82]"}
{"id": "article-22813_52", "title": "A Review of Hereditary Colorectal Cancers -- Prognosis", "content": "In their study, Lee and his colleagues indicated that those with sporadic colorectal cancer (CRC) and a family history of CRC had better overall survival but a cancer recurrence similar to those who did not have a CRC family history. [83]", "contents": "A Review of Hereditary Colorectal Cancers -- Prognosis. In their study, Lee and his colleagues indicated that those with sporadic colorectal cancer (CRC) and a family history of CRC had better overall survival but a cancer recurrence similar to those who did not have a CRC family history. [83]"}
{"id": "article-22813_53", "title": "A Review of Hereditary Colorectal Cancers -- Prognosis", "content": "CRC survivors (5 to 10 years post-diagnosis) reported overall good health-related quality of life but significantly poorer social functioning and more problems with dyspnea, constipation, diarrhea, and finances than controls, mainly among younger subjects. [84]", "contents": "A Review of Hereditary Colorectal Cancers -- Prognosis. CRC survivors (5 to 10 years post-diagnosis) reported overall good health-related quality of life but significantly poorer social functioning and more problems with dyspnea, constipation, diarrhea, and finances than controls, mainly among younger subjects. [84]"}
{"id": "article-22813_54", "title": "A Review of Hereditary Colorectal Cancers -- Complications", "content": "Severe complications during colonoscopy represent the most important adverse effect of colorectal cancer screening programs. The immediate complication occurred in 3.3%, as perforation and hemorrhagic events. However, the following factors increase the risk of early and late complications, including a history of colon disease, a history of anticoagulation, a history of pelvic surgery or abdominal radiotherapy, and a history of perforation. [85]", "contents": "A Review of Hereditary Colorectal Cancers -- Complications. Severe complications during colonoscopy represent the most important adverse effect of colorectal cancer screening programs. The immediate complication occurred in 3.3%, as perforation and hemorrhagic events. However, the following factors increase the risk of early and late complications, including a history of colon disease, a history of anticoagulation, a history of pelvic surgery or abdominal radiotherapy, and a history of perforation. [85]"}
{"id": "article-22813_55", "title": "A Review of Hereditary Colorectal Cancers -- Complications", "content": "After a total colectomy, systemic complications can occur in 22%, mainly in those older than 65 years, due to significant comorbidities, while the incidence of surgical complications was 8%, such as anastomotic leakage, major infections in the wound, and postoperative hemorrhage. [86]", "contents": "A Review of Hereditary Colorectal Cancers -- Complications. After a total colectomy, systemic complications can occur in 22%, mainly in those older than 65 years, due to significant comorbidities, while the incidence of surgical complications was 8%, such as anastomotic leakage, major infections in the wound, and postoperative hemorrhage. [86]"}
{"id": "article-22813_56", "title": "A Review of Hereditary Colorectal Cancers -- Deterrence and Patient Education", "content": "There is a need for educational efforts to raise awareness about CRC, particularly among the young. There is also a need to improve adherence to screening in young patients eligible for screening and to emphasize early evaluation of symptoms. These are\u00a0essential steps to decreasing the burden of CRC in younger patients. [87] Good lifestyle and dietary habits are recommended to reduce the most critical factor in colorectal carcinogenesis starting in the early stages of life. [88]", "contents": "A Review of Hereditary Colorectal Cancers -- Deterrence and Patient Education. There is a need for educational efforts to raise awareness about CRC, particularly among the young. There is also a need to improve adherence to screening in young patients eligible for screening and to emphasize early evaluation of symptoms. These are\u00a0essential steps to decreasing the burden of CRC in younger patients. [87] Good lifestyle and dietary habits are recommended to reduce the most critical factor in colorectal carcinogenesis starting in the early stages of life. [88]"}
{"id": "article-22813_57", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "An interprofessional approach includes a gastroenterologist, oncologist, colorectal surgeon, primary care provider, nurse practitioner (physician and mid-level practitioners), geneticist, nurse genetics counselor, other nursing staff, and pharmacist. Consider offering genetic testing to people with suspected hereditary colorectal cancer and their family members after genetic counseling. [89] Suggestions are that in individuals with a family history in the first degree of classical FAP, the screening strategy is annual colonoscopy from 12 to 15 years, up to 30 to 35 years of age, and then it is suggested to continue screening every five years. [90] [91]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. An interprofessional approach includes a gastroenterologist, oncologist, colorectal surgeon, primary care provider, nurse practitioner (physician and mid-level practitioners), geneticist, nurse genetics counselor, other nursing staff, and pharmacist. Consider offering genetic testing to people with suspected hereditary colorectal cancer and their family members after genetic counseling. [89] Suggestions are that in individuals with a family history in the first degree of classical FAP, the screening strategy is annual colonoscopy from 12 to 15 years, up to 30 to 35 years of age, and then it is suggested to continue screening every five years. [90] [91]"}
{"id": "article-22813_58", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "In the population with suspicion or family history of HNPCC, suggestions are that the screening strategy is a colonoscopy every two years, from 20 to 25 years, or five to ten years before the age of the youngest case diagnosed in the family. [92] [93]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. In the population with suspicion or family history of HNPCC, suggestions are that the screening strategy is a colonoscopy every two years, from 20 to 25 years, or five to ten years before the age of the youngest case diagnosed in the family. [92] [93]"}
{"id": "article-22813_59", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "Studies consistently report that registration and screening reduce CRC incidence and mortality in patients with FAP and LS. [94] [Level 2]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. Studies consistently report that registration and screening reduce CRC incidence and mortality in patients with FAP and LS. [94] [Level 2]"}
{"id": "article-22813_60", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "The MSI test is an effective screening test for Lynch syndrome. However, it must correlate with the panel of markers used or the thresholds used to denote a positive test. [95] [Level 2]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. The MSI test is an effective screening test for Lynch syndrome. However, it must correlate with the panel of markers used or the thresholds used to denote a positive test. [95] [Level 2]"}
{"id": "article-22813_61", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "The\u00a0studies\u00a0indicate that in adenomatous polyposis coli patients with APC promoter, hypermethylation is an early event in carcinogenesis of CRC and could be a valuable diagnostic marker for early-stage CRC. [96] [97] [Level 2]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. The\u00a0studies\u00a0indicate that in adenomatous polyposis coli patients with APC promoter, hypermethylation is an early event in carcinogenesis of CRC and could be a valuable diagnostic marker for early-stage CRC. [96] [97] [Level 2]"}
{"id": "article-22813_62", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "Currently, the evidence of chemoprevention is for NSAIDs, sulindac, and aspirin in low doses that reduce the progression of polyps and the long-term incidence of colorectal cancers in patients with\u00a0FAP\u00a0 and HNPCC, respectively. [98] [Level 2]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. Currently, the evidence of chemoprevention is for NSAIDs, sulindac, and aspirin in low doses that reduce the progression of polyps and the long-term incidence of colorectal cancers in patients with\u00a0FAP\u00a0 and HNPCC, respectively. [98] [Level 2]"}
{"id": "article-22813_63", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "Strict vigilance is necessary for the syndromes associated with CCR and extracolonic\u00a0manifestations, especially LS with endometrial cancer, as well as those mentioned in the differential diagnosis section. [99]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. Strict vigilance is necessary for the syndromes associated with CCR and extracolonic\u00a0manifestations, especially LS with endometrial cancer, as well as those mentioned in the differential diagnosis section. [99]"}
{"id": "article-22813_64", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "The risk factors that increase mortality are advanced age, male sex, African-American race, elevated CEA, and not undergoing curative surgery. Likewise, patients with CRC have an association with an increased risk of cardiovascular death, especially during the first year after diagnosis. [100] [Level 2]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. The risk factors that increase mortality are advanced age, male sex, African-American race, elevated CEA, and not undergoing curative surgery. Likewise, patients with CRC have an association with an increased risk of cardiovascular death, especially during the first year after diagnosis. [100] [Level 2]"}
{"id": "article-22813_65", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "Overall, FOLFOX was the most effective first-line treatment\u00a0[Level I], and FOLFIRI plus cetuximab (KRAS/NRAS wild) was the most effective treatment in terms of long-term survival, Wang and colleagues, in their analysis of 75 RCTs published after 1997. This treatment is preferable for patients with CRC in clinical practice. [101] [Level 1]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. Overall, FOLFOX was the most effective first-line treatment\u00a0[Level I], and FOLFIRI plus cetuximab (KRAS/NRAS wild) was the most effective treatment in terms of long-term survival, Wang and colleagues, in their analysis of 75 RCTs published after 1997. This treatment is preferable for patients with CRC in clinical practice. [101] [Level 1]"}
{"id": "article-22813_66", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "The use\u00a0of bevacizumab represents hope for increased survival and a chance of metastasectomy for patients with metastatic CRC. However, serious adverse events are associated with its use, especially severe hypertension and gastrointestinal perforation, that merit consideration. [102] [Level 1]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. The use\u00a0of bevacizumab represents hope for increased survival and a chance of metastasectomy for patients with metastatic CRC. However, serious adverse events are associated with its use, especially severe hypertension and gastrointestinal perforation, that merit consideration. [102] [Level 1]"}
{"id": "article-22813_67", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "The treating physician should recommend a diet rich in dietary fiber because it decreases CRC risk and post-operative relapses. [103] [104] [105] Currently, there is inadequate data to support the benefits of exercise in the field of colorectal surgery. [106] [107] [Level 3]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. The treating physician should recommend a diet rich in dietary fiber because it decreases CRC risk and post-operative relapses. [103] [104] [105] Currently, there is inadequate data to support the benefits of exercise in the field of colorectal surgery. [106] [107] [Level 3]"}
{"id": "article-22813_68", "title": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes", "content": "Irrespective of the path of treatment (chemotherapy, surgery, etc.), all members of the interprofessional team must follow the patient, off counsel, and alert other team members as necessary when they note a change in the patient's status, including adverse drug events or therapeutic failure or relapse, recording their observations in the patient's medical record. This way, the appropriate measures can be taken to change the treatment regimen to optimize patient outcomes. The interprofessional approach to patient care will benefit the patient and ensure proper therapeutic care. [Level 5]", "contents": "A Review of Hereditary Colorectal Cancers -- Enhancing Healthcare Team Outcomes. Irrespective of the path of treatment (chemotherapy, surgery, etc.), all members of the interprofessional team must follow the patient, off counsel, and alert other team members as necessary when they note a change in the patient's status, including adverse drug events or therapeutic failure or relapse, recording their observations in the patient's medical record. This way, the appropriate measures can be taken to change the treatment regimen to optimize patient outcomes. The interprofessional approach to patient care will benefit the patient and ensure proper therapeutic care. [Level 5]"}
{"id": "article-22813_69", "title": "A Review of Hereditary Colorectal Cancers -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "A Review of Hereditary Colorectal Cancers -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}